Drug induced cicatrizing conjunctivitis (DICC) is defined as a disease in which conjunctival cicatrization develops as a response to the chronic use of inciting topical and, rarely, systemic medications. DICC accounts for up to one third of cases of pseudopemphigoid, a large group of cicatrizing conjunctival diseases sharing similar clinical features to those of mucous membrane pemphigoid (MMP) but generally without the morbidity of progressive scarring or the need for systemic immunosuppression. The preservatives in topical anti-glaucoma medications (AGM) are the most frequently implicated inciting causes of DICC although topical antivirals, vasoconstrictors and mydriatics and some systemic drugs have been implicated. The literature review summarizes the classification, epidemiology, etiopathogenesis, histopathology, clinical presentation, diagnosis, management, and treatment outcomes of DICC in the context of a case series of 23 patients (42 eyes) with AGM induced DICC, from India and the UK. In this series all subjects reacted to preserved AGM with one exception, who also reacted to non-preserved AGM. At diagnosis >70% of eyes showed punctal scarring, inflammation, and forniceal shortening. Pemphigoid studies were negative in the 19/23 patients in whom they were carried out. DICC can be classified as non-progressive, progressive with positive pemphigoid immunopathology or progressive with negative pemphigoid immunopathology. It is unclear whether progressive DICC is a stand-alone disease, or concurrent (or drug induced) ocular MMP. Progressive cases should currently be treated as ocular MMP. The diagnosis can be made clinically when there is rapid resolution of symptoms and inflammation, usually within 1–16 weeks, after withdrawal of suspected inciting medications, ideally by temporary substitution of oral carbonic anhydrase inhibitors. If the response to withdrawal is uncertain, or the progression of inflammation and scarring continues then patients must be evaluated to exclude concurrent (or drug induced) MMP, and other potential causes of CC, for which the treatment and prognosis is different. Management, in addition to withdrawing inciting medications, may require short-term treatment of conjunctival inflammation with steroids, treatment of associated corneal disease with contact lenses or surface reconstructive surgery, control of intra-ocular pressure with non-preserved AGM and, in some, surgery for glaucoma or for trichiasis and entropion.

药物诱导的瘢痕性结膜炎 (DICC) 被定义为一种疾病，其中结膜瘢痕形成是对长期使用刺激性局部药物和很少使用全身药物的反应。DICC 占假性类天疱疮病例的三分之一，假性类天疱疮是一大类瘢痕性结膜疾病，与粘膜类天疱疮 (MMP) 具有相似的临床特征，但通常没有进行性瘢痕形成的发病率或需要全身免疫抑制。局部抗青光眼药物 (AGM) 中的防腐剂是 DICC 最常见的诱因，尽管局部抗病毒药、血管收缩药和散瞳药以及一些全身性药物都与此有关。文献综述总结了分类、流行病学、发病机制、组织病理学、临​​床表现、在来自印度和英国的 23 名 AGM 诱发的 DICC 患者（42 只眼）的病例系列中，DICC 的诊断、管理和治疗结果。在这个系列中，所有受试者都对保存的 AGM 有反应，只有一个例外，他也对未保存的 AGM 有反应。诊断时，>70% 的眼睛显示出泪点疤痕、炎症和穹窿缩短。进行类天疱疮研究的 19/23 名患者呈阴性。DICC 可分为非进行性、进行性类天疱疮免疫病理学阳性或进行性类天疱疮免疫病理学阴性。目前尚不清楚进行性 DICC 是一种独立的疾病，还是并发的（或药物诱发的）眼部 MMP。目前应将进展性病例视为眼部 MMP。当症状和炎症迅速消退时，通常在 1-16 周内，在停用疑似刺激性药物后，最好通过口服碳酸酐酶抑制剂暂时替代，即可做出临床诊断。如果对戒断的反应不确定，或者炎症和瘢痕形成继续发展，则必须对患者进行评估，以排除并发的（或药物诱导的）MMP 和 CC 的其他潜在原因，这些原因的治疗和预后是不同的。管理，除了停用刺激性药物外，可能需要用类固醇短期治疗结膜炎症，用隐形眼镜或表面重建手术治疗相关的角膜疾病，用非保留 AGM 控制眼内压，在某些情况下，